Amid rising geopolitical tensions and trade-related concerns, Asian markets have been navigating a complex landscape, with investor sentiment fluctuating in response to global economic developments. Penny stocks, though often seen as speculative investments from a bygone era, still present intriguing opportunities for growth, particularly when they are backed by sound financial health. In this article, we will explore several penny stocks that stand out for their potential to offer value and growth in the current market climate.

Top 10 Penny Stocks In Asia

Name Share Price Market Cap Financial Health Rating JBM (Healthcare) (SEHK:2161) HK$2.85 HK$2.32B ★★★★★★ Lever Style (SEHK:1346) HK$1.23 HK$776.07M ★★★★★★ Ever Sunshine Services Group (SEHK:1995) HK$1.98 HK$3.42B ★★★★★☆ TK Group (Holdings) (SEHK:2283) HK$2.10 HK$1.75B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.435 SGD176.3M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.13 HK$1.89B ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.25 SGD8.86B ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.18 SGD35.86M ★★★★★★ BRC Asia (SGX:BEC) SGD3.13 SGD858.72M ★★★★★★ Bosideng International Holdings (SEHK:3998) HK$4.59 HK$52.58B ★★★★★★

Click here to see the full list of 1,164 stocks from our Asian Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Yunkang Group Limited is a medical operation service provider in the People’s Republic of China with a market cap of HK$2.15 billion.

Operations: The company’s revenue is primarily derived from its Diagnostic Services segment, which generated CN¥711.88 million.

Market Cap: HK$2.15B

Yunkang Group, with a market cap of HK$2.15 billion, faces challenges as its revenue from Diagnostic Services declined to CN¥711.88 million and net losses increased significantly to CN¥791.68 million for 2024. Despite having more cash than debt and covering short-term liabilities with assets, the company’s return on equity is negative at -68.98%, indicating unprofitability. Recent board changes include the appointment of Dr. Dong Min as an independent non-executive director, potentially bringing valuable biomedicine expertise to the company amidst its financial struggles and lack of dividend payments for 2024.

SEHK:2325 Revenue & Expenses Breakdown as at Jun 2025

Simply Wall St Financial Health Rating: ★★★★★★